Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

5 recruiting trials for Metabolic Dysfunction-Associated Steatotic Liver Disease. Eligibility criteria explained in plain English.

TrialFinderData lists 5 Metabolic Dysfunction-Associated Steatotic Liver Disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 2: 1, Phase 1 / Phase 2: 1.

Research is led by Hospital General Universitario Gregorio Marañon (1), Jinling Hospital, China (1), Seoul National University Hospital (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Hyperbaric oxygen therapy (procedure, 1 trial), followed by Quantitative ultrasound (DeepUSFF), Essential Amino Acids Supplementation intervention.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
5
Total Trials
5
Recruiting Now
0
Phase 3 Trials
5
Sponsors

Track Metabolic Dysfunction-Associated Steatotic Liver Disease trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07658755

Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme

LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in...

Sponsor: Hospital General Universitario Gregorio MarañonEnrolling: 30001 location
RECRUITINGNCT06619808

Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases

The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main...

Sponsor: Jinling Hospital, ChinaEnrolling: 1501 location
RECRUITINGNCT07192159

Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD

This multicenter prospective study aims to evaluate the correlation between quantitative ultrasound fat fraction (USFF) and MRI-PDFF (Proton Density Fat Fraction) for liver fat...

Sponsor: Seoul National University HospitalEnrolling: 622 locations
RECRUITINGPhase 2NCT07459504

SMART Diets for MASLD

This phase 2 trial is a single-site sequential, multiple assignment, randomized trial (SMART) to test and construct a high-quality adaptive intervention of essential amino acids...

Sponsor: Michigan State UniversityEnrolling: 1021 location
RECRUITINGPhase 1 / Phase 2NCT06836609

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or...

This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated...

Sponsor: Regeneron PharmaceuticalsEnrolling: 1323 locations

Frequently Asked Questions

There are currently 5 clinical trials for Metabolic Dysfunction-Associated Steatotic Liver Disease, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Metabolic Dysfunction-Associated Steatotic Liver Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Metabolic Dysfunction-Associated Steatotic Liver Disease, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.